Product Description: Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Ranjana H Advani, et al. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Trial Clin Cancer Res. 2017 Mar 1;23(5):1167-1176./[2]Yip, V., et al., (2024). Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species. Xenobiotica; the fate of foreign compounds in biological systems, 54(8), 511–520.
CAS Number: 1313706-14-7
Molecular Weight: N/A
Compound Purity: 98.25
Research Area: Cancer
Target: Antibody-Drug Conjugates (ADCs);CD22;Microtubule/Tubulin
Deutsch
English
